Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · •The addition of pembrolizumab to taxane-platinum–based chemotherapy followed by an anthracycline significantly increased pathologic complete response (pCR) rates and improved event-free survival in early-stage high-risk TNBC.
15 Φεβ 2023 · Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and is characterized by an aggressive nature and a high rate of recurrence despite neoadjuvant and adjuvant chemotherapy.
TNBC presents a significant treatment challenge due to its aggressive nature and limited targeted therapy options 1, 2.Systemic multiagent chemotherapy improves long-term outcomes and is recommended for stage I–III TNBC disease, with most patients in the current era being treated with neoadjuvant chemotherapy 3.Anthracyclines and cyclophosphamide (AC) have typically constituted the ...
14 Αυγ 2024 · The study aimed to assess the effectiveness and safety of dose-dense AC compared to every 3-week AC in patients with early-stage TNBC undergoing neoadjuvant chemotherapy plus pembrolizumab.
29 Οκτ 2019 · NACT is associated with increased rate of pathologic complete response (pCR), which has been associated with reduced risk of death and recurrence in all subtypes, including TNBC. 3 Residual cancer burden (RCB) after NACT has also been shown to predict disease recurrence and survival across all subtypes. 8 Additionally, neoadjuvant treatment ...
Among patients with TNBC who achieve pCR, the 5-year event free survival (EFS) is approximately 90%, while those with residual disease after NAC, have a poor 5-year EFS of approximately 57%.
2 Φεβ 2022 · The results suggested that 4 cycles of AC followed by weekly paclitaxel (AC*4-wP*12) may be the preferred choice for adjuvant chemotherapy of TNBC patients.
